Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Launched by LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE · May 21, 2025
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well brief statements can help people understand the uncertainties related to the benefits and risks of new cancer drugs. Researchers want to see if these statements can influence how individuals make decisions about using these medications. By participating in this trial, adults from all walks of life will be asked to share their thoughts and feelings about cancer treatments, helping us learn more about effective communication in healthcare.
To be eligible for this trial, participants need to be at least 18 years old, fluent in English, and living in the United States. If you join the study, you will take part in a survey where you’ll read different messages about new cancer drugs and then share your opinions. This is a great opportunity to contribute to important research that could improve how medical information is communicated to patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults 18 years of age and older
- • Adults fluent in English
- • Adults residing in the United States
- Exclusion Criteria:
- • Participants who do not meet each of the 3 inclusion criteria
About London School Of Economics And Political Science
The London School of Economics and Political Science (LSE) is a prestigious academic institution renowned for its rigorous research and advanced studies in the social sciences, including economics, politics, and sociology. As a clinical trial sponsor, LSE leverages its interdisciplinary expertise to design and conduct innovative research that addresses pressing health and social issues. Committed to advancing evidence-based policy and practice, LSE collaborates with various stakeholders to ensure that its clinical trials are methodologically sound and ethically conducted, ultimately contributing to the improvement of public health outcomes and informed decision-making in healthcare systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported